Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Lucira Health Terminates COVID-19 Test-Related Patent Agreement With Eiken Chemical

  • According to an SEC filingLucira Health Inc (NASDAQ:LHDX) has terminated a Patent License with Eiken Chemical Co Ltd, effective May 12, 2022.
  • The Company terminated the agreement because certain Eiken Licensed Patents have expired, all of which are locations in which the Company operates.
  • According to the agreement announced in July 2020, Eiken granted Lucira Health a sublicensable, non-exclusive license under certain patents, relating, in part, to loop-mediated isothermal amplification for nucleic acid-based COVID-19 in-vitro diagnostic tests in the U.S. 
  • Related: Lucira Health Shares Fall After Announcing Debt Facility Of $80M.
  • The Company also has limited have-made rights for the Eiken Licensed Patents. 
  • Following termination of the agreement, the Company will not be required to make any future payments under the contract. 
  • Price Action: LHDX shares closed 6.54% lower at $2.86 on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.